Gateway Advisory’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Gateway Advisory’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-4,200	Closed	-$480K	–	97
2017 Q1	$480K	Buy	+4,200	New	+$449K	0.15%	52
2016 Q1	–	Sell	-1,900	Closed	-$271K	–	55
2015 Q4	$271K	Buy	+1,900	New	+$219K	0.12%	39
2015 Q1	–	Sell	-4,050	Closed	-$272K	–	43
2014 Q4	$272K	Buy	+4,050	New	+$251K	0.12%	32

Other funds holding CBPO

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

HIM

Hermes Investment Management London Uk, United Kingdom $7.52B AUM 20.67% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Gateway Advisory's CBPO Position: Q2 2017 in Review

Gateway Advisory sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2017, closing a stake of 4,200 shares — an estimated $480K sold.

Gateway Advisory first reported a position in CBPO in Q4 2014 and held it in 3 quarters. The position peaked at $480K in Q1 2017. 119 funds tracked by Wall St. Rank hold CBPO as of Q2 2017.

Gateway Advisory reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2017 after selling out during the quarter.
Gateway Advisory sold 4,200 China Biologic Products Holdings, Inc. shares in Q2 2017, an estimated $480K.
Gateway Advisory first reported a position in China Biologic Products Holdings, Inc. in Q4 2014 and held it in 3 quarters.
Gateway Advisory's China Biologic Products Holdings, Inc. position peaked at $480K in Q1 2017.
119 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2017.

Based on Gateway Advisory's 13F filing for Q2 2017, filed 28 Jul 2017.